Osteoporosis International

, Volume 19, Issue 10, pp 1363–1368 | Cite as

Assessing response to osteoporosis therapy

  • E. M. LewieckiEmail author
  • N. B. Watts
Special Feature


Patients treated with pharmacological agents to improve bone strength and reduce fracture risk may not achieve optimal skeletal benefit for reasons that include poor compliance and persistence, inadequate calcium and vitamin D intake, malabsorption, and medications or co-morbidities with adverse skeletal effects. Monitoring the effects of therapy can inform the patient and physician that the drug is having its expected skeletal response. Treatment is often monitored with serial bone mineral density (BMD) measurements using dual-energy X-ray absorptiometry or bone turnover markers (BTMs). Stable or increasing BMD is associated with reduced fracture risk in clinical trials, and is considered an indication of good response to therapy in individual patients outside of clinical trials. There are many differences between subjects in clinical trials and patients being treated in clinical practice. Thus, although defining a clinical practice patient as a “nonresponder” or “suboptimal responder” to treatment is problematic, a pragmatic approach would be to consider evaluation for contributing factors and possible changes in therapy in patients who have a statistically significant decrease in BMD, do not have the expected change in BTMs, or have a fracture.


Bone mineral density Bone turnover marker Dual-energy X-ray absorptiometry Fracture Nonresponder Osteoporosis Responder Treatment 


Conflicts of interest



  1. 1.
    Kanis JA, on behalf of the World Health Organization Scientific Group (2007) (2007) Assessment of osteoporosis at the primary health-care level. Technical Report. World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK: Printed by the University of Sheffield.Google Scholar
  2. 2.
    Lotz JC, Cheal EJ, Hayes WC (1991) Fracture prediction for the proximal femur using finite element models: Part I–Linear analysis. J Biomechan Eng 113:353–360CrossRefGoogle Scholar
  3. 3.
    Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312:1254–1259PubMedGoogle Scholar
  4. 4.
    Kanis JA, the WHO Study Group (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Osteoporos Int 4:368–381PubMedCrossRefGoogle Scholar
  5. 5.
    Cranney A, Tugwell P, Wells G, Guyatt G (2002) Systematic reviews of randomized trials in osteoporosis: Introduction and methodology. Endocr Rev 23:497–507Google Scholar
  6. 6.
    Wasnich RD, Miller PD (2000) Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 85:231–236PubMedCrossRefGoogle Scholar
  7. 7.
    Mazess R, Chesnut CH III, McClung M, Genant H (1992) Enhanced precision with dual-energy X-ray absorptiometry. Calcif Tissue Int 51:14–17PubMedCrossRefGoogle Scholar
  8. 8.
    Binkley N, Bilezikian JP, Kendler DL, Leib ES, Lewiecki EM, Petak SM (2006) Official Positions of the International Society for Clinical Densitometry and Executive Summary of the 2005 Position Development Conference. J Clin Densitom 9:4–14PubMedCrossRefGoogle Scholar
  9. 9.
    MacLean C, Newberry S, Maglione M, McMahon M, Ranganath V, Suttorp M, Mojica W, Timmer M, Alexander A, McNamara M, Desai SB, Zhou A, Chen S, Carter J, Tringale C, Valentine D, Johnsen B, Grossman J (2008) Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 148:197–213PubMedGoogle Scholar
  10. 10.
    US Department of Health and Human Services (2004) Bone Health and Osteoporosis: A Report of the Surgeon General. US Department of Health and Human Services, Office of the Surgeon General.Google Scholar
  11. 11.
    Cramer JA, Gold DT, Silverman SL, Lewiecki EM (2007) A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 18:1023–1031PubMedCrossRefGoogle Scholar
  12. 12.
    Diez-Perez A, Gonzalez-Macias J (2008) Inadequate responders to osteoporosis treatment: proposal for an operational definition. Osteoporos Int DOI  10.1007/s00198-008-0659-2
  13. 13.
    Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822PubMedCrossRefGoogle Scholar
  14. 14.
    Garnero P, Hausherr E, Chapuy M-C, Marcelli C, Grandjean H, Muller C, Cormier C, Breart G, Meunier PJ, Delmas PD (1996) Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study. J Bone Miner Res 11:1531–1538PubMedCrossRefGoogle Scholar
  15. 15.
    Dowd R, Recker RR, Heaney RP (2000) Study subjects and ordinary patients. Osteoporos Int 11:533–536PubMedCrossRefGoogle Scholar
  16. 16.
    Chesnut CH III, Silverman S, Andriano K, Genant H, Gimona A, Harris S, Kiel D, LeBoff M, Maricic M, Miller P, Moniz C, Peacock M, Richardson P, Watts N, Baylink D, PROOF Study Group (2000) A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. Am J Med 109:267–276PubMedCrossRefGoogle Scholar
  17. 17.
    Watts NB, Miller PMR, Chen P, Arsenault J, Krohn K (2008) Vertebral fracture risk is reduced for women who lose femoral neck bone mineral density during teriparatide therapy [abstract]. J Clin Densitom 11:In pressGoogle Scholar
  18. 18.
    Chapurlat RD, Palermo L, Ramsay P, Cummings SR, The Fracture Intervention Trial (2005) Risk of fracture among women who lose bone density during treatment with alendronate. Osteoporos Int 16:842–848PubMedCrossRefGoogle Scholar
  19. 19.
    Baim S, Binkley N, Bilezikian JP, Kendler DL, Hans DB, Lewiecki EM, Silverman S (2008) Official positions of the International Society for Clinical Densitometry and executive summary of the 2007 position development conference. J Clin Densitom 11:75–91PubMedCrossRefGoogle Scholar
  20. 20.
    Lewiecki EM, Rudolph LA (2002) How common is loss of bone mineral density in elderly clinical practice patients receiving oral bisphosphonate therapy for osteoporosis? J Bone Miner Res 17(Suppl 2):S367Google Scholar
  21. 21.
    Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, Thompson DE, Ewing SK, Delmas PD (2004) Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 19:1250–1258PubMedCrossRefGoogle Scholar
  22. 22.
    Lewiecki EM (2003) Nonresponders to osteoporosis therapy. J Clin Densitom 6:307–314PubMedCrossRefGoogle Scholar
  23. 23.
    Del Puente A, Scognamiglio A, Itto E, Ferrara G, Oriente P (2000) Intramuscular clodronate in nonresponders to oral alendronate therapy for osteoporosis. J Rheumatol 27:1980–1983PubMedGoogle Scholar
  24. 24.
    Adami S, Isaia G, Luisetto G, Minisola S, Sinigaglia L, Gentilella R, Agnusdei D, Iori N, Nuti R (2006) Fracture incidence and characterization in patients on osteoporosis treatment: the ICARO study. J Bone Miner Res 21:1565–1570PubMedCrossRefGoogle Scholar
  25. 25.
    Heckman GA, Papaioannou A, Sebaldt RJ, Ioannidis G, Petrie A, Goldsmith C, Adachi JD (2002) Effect of vitamin D on bone mineral density of elderly patients with osteoporosis responding poorly to bisphosphonates. BMC Musculoskelet Disord 3:6PubMedCrossRefGoogle Scholar
  26. 26.
    Sawka AM, Adachi JD, Ioannidis G, Olszynski WP, Brown JP, Hanley DA, Murray T, Josse R, Sebaldt RJ, Petrie A, Tenenhouse A, Papaioannou A, Goldsmith CH (2003) What predicts early fracture or bone loss on bisphosphonate therapy? J Clin Densitom 6:315–322PubMedCrossRefGoogle Scholar
  27. 27.
    Jakob F, Marin F, Martin-Mola E, Torgerson D, Fardellone P, Adami S, Thalassinos NC, Sykes D, Melo-Gomes J, Chinn C, Nicholson T, Cooper C (2006) Characterization of patients with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO). QJM 99:531–543PubMedCrossRefGoogle Scholar
  28. 28.
    Obermayer-Pietsch B, Nickelsen T, Marin F, Barker C, Hadji P, Farrerons J, Audran M, Boonen S, Anastasilakis A, McCloskey E (2006) Response of BMD to 24 months of teriparatide (rhPTH 1–34) in patients with and without prior antiresorptive treatment: final results from the EUROFORS study. J Bone Miner Res 21(Suppl 1):S43Google Scholar
  29. 29.
    NICE (National Institute for Clinical Excellence) (2004) Final appraisal determination- secondary prevention of osteoporotic fragility fractures in postmenopausal women. NICE:Google Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2008

Authors and Affiliations

  1. 1.New Mexico Clinical Research & Osteoporosis CenterAlbuquerqueUSA
  2. 2.University of Cincinnati Bone Health and Osteoporosis CenterCincinnatiUSA

Personalised recommendations